Trial Profile
Patients with advanced renal cell carcinoma treated with first-line sunitinib - Hypothyroidism a potential indicator of prognosis
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 01 Sep 2015 New trial record